Read by QxMD icon Read


shared collection
36 papers 0 to 25 followers
Bei Ye, Daniel R van Langenberg
Oral mesalazine (also known as mesalamine) is a 5-aminosalicylic acid compound used in the treatment of mild to moderate ulcerative colitis, with high rates of efficacy in induction and maintenance of remission. The therapeutic effect of mesalazine occurs topically at the site of diseased colonic mucosa. A myriad of oral mesalazine preparations have been formulated with various drug delivery methods to minimize systemic absorption and maximise drug availability at the inflamed colonic epithelium. It remains unclear whether different oral mesalazine formulations are bioequivalent...
November 6, 2015: World Journal of Gastrointestinal Pharmacology and Therapeutics
Ashwin N Ananthakrishnan
No abstract text is available yet for this article.
May 2016: Clinical Gastroenterology and Hepatology
Jong Wook Kim, Sun-Jin Boo, Byong Duk Ye, Chang Lae Kim, Suk-Kyun Yang, Jihun Kim, Sun A Kim, Sang Hyoung Park, Soo-Kyung Park, Dong-Hoon Yang, Kee Wook Jung, Kyung-Jo Kim, Jeong-Sik Byeon, Seung-Jae Myung, Jin-Ho Kim
BACKGROUND AND AIMS: Clinical usefulness of cytomegalovirus (CMV) antigenemia assay and blood CMV polymerase chain reaction (PCR) in patients with ulcerative colitis (UC) needs to be evaluated. METHODS: Medical records of moderate to severe UC patients between January 2001 and December 2012 were reviewed retrospectively. Diagnostic performances of CMV antigenemia assay and blood PCR to predict CMV colitis, and clinical outcome according to the results were analyzed...
July 2014: Journal of Crohn's & Colitis
Steven Naymagon, Michael Mikulasovich, Xianyong Gui, Thomas A Ullman, Noam Harpaz
BACKGROUND & AIMS: Giant inflammatory polyposis (GIP), characterized by mass-like agglomerations of inflammatory polyps, is a rare complication of inflammatory bowel disease (IBD). We reviewed a series of cases of GIP to determine its diagnostic impact on the clinical and pathologic distinction between ulcerative colitis (UC) and colonic Crohn's disease (CD). METHODS: All colons with GIP resected over a 13-year period were identified prospectively and the corresponding clinical and pathologic records were reviewed...
July 2014: Journal of Crohn's & Colitis
Guillaume Bouguen, Barrett G Levesque, Suresh Pola, Elisabeth Evans, William J Sandborn
BACKGROUND: Mucosal healing (MH) as a treatment target for ulcerative colitis is of growing interest because it is associated with improved clinical outcomes. However, the feasibility and probability of reaching MH in clinical practice is unknown. We therefore evaluated the feasibility of "treating to target" according to endoscopic findings to reach MH. METHODS: All endoscopic outcomes of patients with ulcerative colitis followed in a single inflammatory bowel disease unit from 2011 to 2012 were reviewed and subsequent therapeutic management...
February 2014: Inflammatory Bowel Diseases
Sarah L Kempster, Arthur Kaser
No abstract text is available yet for this article.
September 2014: Gut
Jose-Manuel Benitez, Marie-Alice Meuwis, Catherine Reenaers, Catherine Van Kemseke, Paul Meunier, Edouard Louis
Crohn's disease is characterised by recurrent and/or chronic inflammation of the gastrointestinal tract leading to cumulative intestinal tissue damage. Treatment tailoring to try to prevent this tissue damage as well as achieve optimal benefit/risk ratio over the whole disease course is becoming an important aspect of Crohn's disease management. For decades, clinical symptoms have been the main trigger for diagnostic procedures and treatment strategy adaptations. However, the correlation between symptoms and intestinal lesions is only weak...
December 2013: Gut
Holm H Uhlig
Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, has multifactorial aetiology with complex interactions between genetic and environmental factors. Over 150 genetic loci are associated with IBD. The genetic contribution of the majority of those loci towards explained heritability is low. Recent studies have reported an increasing spectrum of human monogenic diseases that can present with IBD-like intestinal inflammation. A substantial proportion of patients with those genetic defects present with very early onset of intestinal inflammation...
December 2013: Gut
N Pedersen, A Bortoli, D Duricova, R D Inca, M R Panelli, J P Gisbert, G Zoli, A López-Sanromán, F Castiglione, G Riegler, V Annese, P Gionchetti, A Prada, E D Pont, A Timmer, C Felley, M Shuhaibar, E V Tsianos, C Dejaco, F J Baert, T Jess, M Lebech, D W Hommes, P Munkholm
BACKGROUND: The impact of pregnancy on the course of IBD is still controversial. AIM: To investigate the impact of pregnancy on IBD and to search for factors with potential impact on remission. METHODS: Pregnant IBD women from 12 European countries were enrolled between January 2003 and December 2006 and compared at conception (1:1) with nonpregnant IBD women. Data on disease course were prospectively collected at each trimester during pregnancy and in the postpartum (6 months) using a standardised questionnaire...
September 2013: Alimentary Pharmacology & Therapeutics
W Kruis
No abstract text is available yet for this article.
August 2013: Alimentary Pharmacology & Therapeutics
R Khanna, B D Sattin, W Afif, E I Benchimol, E-J Bernard, A Bitton, B Bressler, R N Fedorak, S Ghosh, G R Greenberg, J K Marshall, R Panaccione, E G Seidman, M S Silverberg, A H Steinhart, R Sy, G Van Assche, T D Walters, W J Sandborn, B G Feagan
BACKGROUND: Tumour necrosis factor (TNF)-antagonists have an established role in the treatment of inflammatory bowel diseases (IBDs), however, subtherapeutic drug levels and the formation of anti-drug antibodies (ADAs) may decrease their efficacy. AIM: The evidence supporting the use of therapeutic drug monitoring (TDM) based clinical algorithms for infliximab (IFX) and their role in clinical practice will be discussed. METHODS: The literature was reviewed to identify relevant articles on the measurement of IFX levels and antibodies-to-infliximab...
September 2013: Alimentary Pharmacology & Therapeutics
A Croft, A Walsh, J Doecke, R Cooley, M Howlett, G Radford-Smith
BACKGROUND: Up to 40% of patients who present with acute severe ulcerative colitis (UC) fail to make an adequate response to intravenous corticosteroids. Ciclosporin or infliximab are currently employed as salvage therapy in this clinical scenario. AIM: To compare clinical outcomes in patients treated with ciclosporin or infliximab in the setting of steroid-refractory acute severe UC. METHODS: A prospective study of 83 consecutive presentations of steroid-refractory acute severe UC from 1999 to 2009 was conducted...
August 2013: Alimentary Pharmacology & Therapeutics
Julián Panés, Antonio López-Sanromán, Fernando Bermejo, Valle García-Sánchez, Maria Esteve, Yolanda Torres, Eugeni Domènech, Marta Piqueras, María Gomez-García, Ana Gutiérrez, Carlos Taxonera, Miquel Sans
BACKGROUND & AIMS: A small placebo-controlled trial reported the efficacy of mercaptopurine therapy for children newly diagnosed with Crohn's disease, yet little is known about the efficacy of early thiopurine therapy in adults. METHODS: We performed a prospective double-blind trial of adult patients with a recent (<8 weeks) diagnosis of Crohn's disease. Patients were randomly assigned to groups given azathioprine (2.5 mg · kg(-1) · day(-1), n = 68) or placebo (n = 63) at 31 hospitals from February 2006 to September 2009...
October 2013: Gastroenterology
W J Sandborn, D E Elliott, J Weinstock, R W Summers, A Landry-Wheeler, N Silver, M D Harnett, S B Hanauer
BACKGROUND: Recent evidence suggests that embryonated eggs of the porcine whipworm Trichuris suis ova (TSO) may be an effective treatment for inflammatory bowel disease (IBD). AIM: To assess the safety and tolerability of TSO following a single dose in patients with Crohn's disease. METHODS: This was a sequential dose-escalation (500, 2500 and 7500 viable embryonated TSO), randomised, double-blind, placebo-controlled study to evaluate the safety of a single dose of oral suspension TSO in patients with Crohn's disease...
August 2013: Alimentary Pharmacology & Therapeutics
J D Ryan, M S Silverberg, W Xu, L A Graff, L E Targownik, J R Walker, R Carr, I Clara, N Miller, L Rogala, C N Bernstein
BACKGROUND: Predictors of complicated Crohn's disease (CD), defined as stricturing or penetrating behaviour, and surgery have largely been derived from referral centre populations. AIM: To investigate whether serological markers, susceptibility genes or psychological characteristics are associated with complicated CD or surgery in a population-based cohort. METHODS: One hundred and eighty-two members of the Manitoba IBD Cohort with CD phenotyped using the Montreal classification underwent genetic and serological analysis at enrolment and after 5 years...
August 2013: Alimentary Pharmacology & Therapeutics
S J Mehta, A R Silver, J O Lindsay
BACKGROUND: Chronic active ulcerative colitis (UC) is associated with significant morbidity, loss of productivity, increased colorectal cancer risk and cost. Up to 18% of patients suffer chronic active disease, with 30% requiring colectomy at 10 years. The management remains challenging given the relatively few clinical trials in this area. AIM: To summarise the evidence regarding optimal management strategies for patients with chronic active UC of differing disease extents and degrees of treatment refractoriness...
July 2013: Alimentary Pharmacology & Therapeutics
Jin Ha Lee, Jae Hee Cheon, Seong Woo Jeon, Byong Duk Ye, Suk-Kyun Yang, Young-Ho Kim, Kang-Moon Lee, Jong Pil Im, Joo Sung Kim, Chang Kyun Lee, Hyo Jong Kim, Eun Young Kim, Kyeong Ok Kim, Byung Ik Jang, Won Ho Kim
BACKGROUND: Although infliximab is widely accepted as a therapeutic option for inflammatory bowel disease, its therapeutic efficacy for the treatment of intestinal Behçet's disease (BD) is unknown. We investigated the short-term and long-term response rates to infliximab in intestinal BD and predictive factors of sustained treatment response following infliximab treatment. METHODS: This study was conducted using a retrospective noncontrolled review of medical records from 8 tertiary hospitals in Korea...
August 2013: Inflammatory Bowel Diseases
Linda A Feagins, Shelby D Melton, Ramiz Iqbal, Kerry B Dunbar, Stuart J Spechler
BACKGROUND: For patients with ulcerative colitis (UC) who have colonoscopy while their disease is in clinical remission, the clinical implications of finding histologic abnormalities of colitis are not clear. METHODS: We reviewed the medical records of patients with UC who had elective colonoscopy at our VA Medical Center while their UC was in clinical remission and who had at least 6 months of follow-up data available. The Mayo endoscopic subscore was used to assess endoscopic disease activity...
June 2013: Inflammatory Bowel Diseases
Maggie Ham, Alan Moss
No abstract text is available yet for this article.
November 2013: Journal of Crohn's & Colitis
Valerie Pittet, Florian Froehlich, Michel H Maillard, Christian Mottet, Jean-Jacques Gonvers, Christian Felley, John-Paul Vader, Bernard Burnand, Pierre Michetti, Alain Schoepfer
BACKGROUND: Safety and economic issues have increasingly raised concerns about the long term use of immunomodulators or biologics as maintenance therapies for Crohn's disease (CD). Despite emerging evidence suggesting that stopping therapy might be an option for low risk patients, criteria identifying target groups for this strategy are missing, and there is a lack of recommendations regarding this question. METHODS: Multidisciplinary European expert panel (EPACT-II Update) rated the appropriateness of stopping therapy in CD patients in remission...
November 2013: Journal of Crohn's & Colitis
2016-05-06 07:33:41
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"